Cenobamate Efficacy in Individuals With Autoimmune Epilepsy
A legfontosabb adatok
- Hol
- Rome (Olaszország)A helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek autoimmun epilepsziájuk van, cenobamát nevű rohamellenes gyógyszert kezdenek szedni, és 3 hónapja stabil kezelést kapnak.
- Életkor
- 18 évnél idősebb
- Nem
- Mindkét nem
- A betegség stádiuma
- Autoimmun epilepszia, az ILAE 2017 szerinti kritériumok alapján megállapítva.
- Korábbi kezelés
- Stabil immunterápia és rohamellenes gyógyszerek a cenobamát kezdete előtti 3 hónapban.
A részvétel fő kizáró okai
- Családi rövid QT-szindróma
- Allergia a cenobamátra vagy segédanyagaira
- Korábbi súlyos gyógyszermellékhatás, például DRESS vagy Stevens-Johnson-szindróma
- Nem tud olaszul írni és olvasni
- Terhesség vagy szoptatás
Gépi kiolvasás: 2026. november 9.
Helyszínek itt: Olaszország
- UOC di NeurologiaRome, OlaszországNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
A vizsgálat adatai
- Ki végzi
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Azonosító
- NCT07474285
- A regiszteradat frissítve
- 2026. március 16.
- Eredeti leírás
Over the last decades, multiple neuronal autoantibodies directed against intracellular or cell-surface antigens have been identified in association with epilepsy and encephalopathy. In some patients with immune-mediated brain disorders, seizures persist and become chronic despite treatment with antiseizure medications (ASMs) and immunotherapy. This condition is particularly common in patients with antibodies against glutamic acid decarboxylase 65 (GAD65) or onconeural antigens (e.g., Hu, Ma2, and CRMP5/CV2). The persistence of seizures despite immunotherapy suggests the development of a sustained epileptogenic predisposition, consistent with the current conceptual definition of epilepsy.A teljes eredeti leírásKevesebb
Evaluation of the Efficacy and Safety of Cenobamate in Individuals With Autoimmune Epilepsy: a Real-world Study
Over the last decades, multiple neuronal autoantibodies directed against intracellular or cell-surface antigens have been identified in association with epilepsy and encephalopathy. In some patients with immune-mediated brain disorders, seizures persist and become chronic despite treatment with antiseizure medications (ASMs) and immunotherapy. This condition is particularly common in patients with antibodies against glutamic acid decarboxylase 65 (GAD65) or onconeural antigens (e.g., Hu, Ma2, and CRMP5/CV2). The persistence of seizures despite immunotherapy suggests the development of a sustained epileptogenic predisposition, consistent with the current conceptual definition of epilepsy.
Cenobamate (CNB) is a recently approved antiseizure medication for the treatment of focal-onset seizures, with or without secondary generalization, in adults whose epilepsy remains uncontrolled despite prior treatment with at least two ASMs. CNB has demonstrated broad antiseizure efficacy, likely due to its dual mechanism of action: inhibition of the persistent component of voltage-gated sodium currents and positive allosteric modulation of GABAA receptors through a non-benzodiazepine mechanism.
Recent retrospective data suggest that CNB may be effective in patients with anti-GAD65 autoimmune encephalitis, potentially compensating for impaired GABAergic neurotransmission associated with these antibodies. Other studies have also suggested that GABA-enhancing ASMs, such as benzodiazepines and barbiturates, may be beneficial in anti-GABAAR encephalitis, whereas sodium channel blockers may be effective in LGI1/CASPR2 antibody-associated encephalitis by reducing repetitive neuronal firing through interactions with voltage-gated sodium channels.
The primary objective of this study is to determine the proportion of patients achieving a ≥50% reduction in seizure frequency during the 24 weeks following initiation of cenobamate compared with baseline seizure frequency.
Secondary objectives include:
evaluating the proportion of patients achieving ≥75% and 100% seizure reduction,
assessing the safety and tolerability of cenobamate by documenting the frequency and severity of adverse events,
analyzing the impact of CNB treatment on quality of life using validated scales such as the Clinical Global Impression (CGI) and the Hospital Anxiety and Depression Scale (HADS),
exploring treatment efficacy according to the specific autoantibody subtype associated with autoimmune epilepsy.
Bevonási feltételek: Age >18 years; Signed informed consent; Diagnosis of autoimmune epilepsy according to the ILAE 2017 criteria; Stable treatment regimen with immunotherapy and antiseizure medications (ASMs) during the 3 months preceding the initiation of CNB treatment.
Kizáró feltételek: Hypersensitivity to CNB or any of its excipients; History of severe adverse drug reactions, including DRESS and Stevens-Johnson syndrome; Diagnosis of familial short QT syndrome; Inability to read and write in Italian; Pregnant or breastfeeding patients.